AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
Authors: Erlichman, C Adjei, AA Alberts, SR Sloan, JA Goldberg, RM Pitot, HC Rubin, J Atherton, PJ Klee, GG Humphrey, R
Citation: C. Erlichman et al., Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566, ANN ONCOL, 12(3), 2001, pp. 389-395
Dyspnea in cancer patients: Prevalence and associated factors
Authors: Dudgeon, DJ Kristjanson, L Sloan, JA Lertzman, M Clement, K
Citation: Dj. Dudgeon et al., Dyspnea in cancer patients: Prevalence and associated factors, J PAIN SYMP, 21(2), 2001, pp. 95-102
Patients with reconstruction of craniofacial or intraoral defects: Development of instruments to measure quality of life
Authors: Sloan, JA Tolman, DE Anderson, JD Sugar, AW Wolfaardt, JF Novotny, P
Citation: Ja. Sloan et al., Patients with reconstruction of craniofacial or intraoral defects: Development of instruments to measure quality of life, INT J O M I, 16(2), 2001, pp. 225-245
Methodologic lessons learned from hot flash studies
Authors: Sloan, JA Loprinzi, CL Novotny, PJ Barton, DL Lavasseur, BI Windschitl, H
Citation: Ja. Sloan et al., Methodologic lessons learned from hot flash studies, J CL ONCOL, 19(23), 2001, pp. 4280-4290
A simple stratification factor prognostic for survival in advanced cancer:The Good/Bad/Uncertain index
Authors: Sloan, JA Loprinzi, CL Laurine, JA Novotny, PJ Vargas-Chanes, D Krook, JE O'Connell, MJ Kugler, JW Tirona, MT Kardinal, CG Wiesenfeld, M Tschetter, LK Hatfield, AK Schaefer, PL
Citation: Ja. Sloan et al., A simple stratification factor prognostic for survival in advanced cancer:The Good/Bad/Uncertain index, J CL ONCOL, 19(15), 2001, pp. 3539-3546
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
Authors: Sloan, JA Atherton, P Reid, J Pilot, HC Erlichman, C Schaaf, L
Citation: Ja. Sloan et al., Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide, CANC CHEMOT, 48(3), 2001, pp. 241-249
Design considerations for efficient prostate cancer chemoprevention trials
Authors: Lee, JD Lieberman, R Sloan, JA Piantadosi, S Lippman, SM
Citation: Jd. Lee et al., Design considerations for efficient prostate cancer chemoprevention trials, UROLOGY, 57(4A), 2001, pp. 205-212
Quality of life endpoints in prostate chemoprevention trials
Authors: Sloan, JA Varricchio, C
Citation: Ja. Sloan et C. Varricchio, Quality of life endpoints in prostate chemoprevention trials, UROLOGY, 57(4A), 2001, pp. 235-240
Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia - A North Central Cancer Treatment Group exploratory investigation
Authors: Jatoi, A Loprinzi, CL Sloan, JA Klee, GG Windschitl, HE
Citation: A. Jatoi et al., Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia - A North Central Cancer Treatment Group exploratory investigation, CANCER, 92(3), 2001, pp. 629-633
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer
Authors: Bonner, JA Sloan, JA Rowland, KM Klee, GG Kugler, JW Mailliard, JA Wiesenfeld, M Krook, JE Maksymiuk, AW Shaw, EG Marks, RS Perez, EA
Citation: Ja. Bonner et al., Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer, CLIN CANC R, 6(2), 2000, pp. 597-601
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
Authors: Adjei, AA Erlichman, C Sloan, JA Reid, JM Pitot, HC Goldberg, RM Peethambaram, P Atherton, P Hanson, LJ Alberts, SR Jett, J
Citation: Aa. Adjei et al., Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors, J CL ONCOL, 18(8), 2000, pp. 1748-1757
Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial
Authors: Martenson, JA Bollinger, JW Sloan, JA Novotny, PJ Urias, RE Michalak, JC Shanahan, TG Mailliard, JA Levitt, R
Citation: Ja. Martenson et al., Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial, J CL ONCOL, 18(6), 2000, pp. 1239-1245
Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group trial
Authors: Quella, SK Loprinzi, CL Barton, DL Knost, JA Sloan, JA LaVasseur, BI Swan, D Krupp, KR Miller, KD Novotny, PJ
Citation: Sk. Quella et al., Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group trial, J CL ONCOL, 18(5), 2000, pp. 1068-1074
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
Authors: Adjei, AA Klein, CE Kastrissios, H Goldberg, RM Alberts, SR Pitot, HC Sloan, JA Reid, JM Hanson, LJ Atherton, P Rubin, J Erlichman, C
Citation: Aa. Adjei et al., Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity, J CL ONCOL, 18(5), 2000, pp. 1116-1123
Sex differences in fluorouracil-induced stomatitis
Authors: Sloan, JA Loprinzi, CL Novotny, PJ Okuno, S Nair, S Barton, DL
Citation: Ja. Sloan et al., Sex differences in fluorouracil-induced stomatitis, J CL ONCOL, 18(2), 2000, pp. 412-420
On appetite and its loss
Authors: Jatoi, A Kumar, S Sloan, JA Nguyen, PL
Citation: A. Jatoi et al., On appetite and its loss, J CL ONCOL, 18(15), 2000, pp. 2930-2932
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer
Authors: Weitz, JJ Marschke, RF Sloan, JA Grill, JP Jett, JR Knost, JA Hatfield, AK Zenk, DW Bate, WW Schaefer, PL
Citation: Jj. Weitz et al., A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer, LUNG CANC, 28(2), 2000, pp. 157-162
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
Authors: Loprinzi, CL Kugler, JW Sloan, JA Mailliard, JA LaVasseur, BI Barton, DL Novotny, PJ Dakhil, SR Rodger, K Rummans, TA Christensen, BJ
Citation: Cl. Loprinzi et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial, LANCET, 356(9247), 2000, pp. 2059-2063
Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
Authors: Frost, MH Schaid, DJ Sellers, TA Slezak, JM Arnold, PG Woods, JE Petty, PM Johnson, JL Sitta, DL McDonnell, SK Rummans, TA Jenkins, RB Sloan, JA Hartmann, LC
Citation: Mh. Frost et al., Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy, J AM MED A, 284(3), 2000, pp. 319-324
A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
Authors: Adjei, AA Erlichman, C Davis, JN Cutler, DL Sloan, JA Marks, RS Hanson, LJ Svingen, PA Atherton, P Bishop, WR Kirschmeier, P Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Incremental costs of enrolling cancer patients in clinical trials: a population-based study
Authors: Wagner, JL Alberts, SR Sloan, JA Cha, S Killian, J O'Connell, MJ Van Grevenhof, P Lindman, J Chute, CG
Citation: Jl. Wagner et al., Incremental costs of enrolling cancer patients in clinical trials: a population-based study, J NAT CANC, 91(10), 1999, pp. 847-853
Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases
Authors: Anderson, PM Markovic, SN Sloan, JA Clawson, ML Wylam, M Arndt, CAS Smithson, WA Burch, P Gornet, M Rahman, E
Citation: Pm. Anderson et al., Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases, CLIN CANC R, 5(9), 1999, pp. 2316-2323
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Authors: Pitot, HC McElroy, EA Reid, JR Windebank, AJ Sloan, JA Erlichman, C Bagniewski, PG Walker, DL Rubin, J Goldberg, RM Adjei, AA Ames, MM
Citation: Hc. Pitot et al., Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, CLIN CANC R, 5(3), 1999, pp. 525-531
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma
Authors: Bonner, JA Sloan, JA Shanahan, TG Brooks, BJ Marks, RS Krook, JE Gerstner, JB Maksymiuk, A Levitt, R Mailliard, JA Tazelaar, HD Hillman, S Jett, JR
Citation: Ja. Bonner et al., Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma, J CL ONCOL, 17(9), 1999, pp. 2681-2691
Risultati: 1-25 | 26-32